- •
Office-based management of the bladder can be used in low risk-stratified patients to reduce costs and burden of care.
- •
Smoking cessation and narrow-band imaging may play important underevaluated roles in the future management of bladder cancer.
Office-based Management of Nonmuscle Invasive Bladder Cancer
Section snippets
Key points
Natural history of noninvasive bladder cancer
Over 2.7 million people live with bladder cancer,1 and over 380,000 incident bladder tumors were identified annually worldwide in 2008,2 including 73,000 tumors in the United States.3 In fact, bladder cancer is the fifth most common cancer in the United States. The worldwide age-standardized rate (ASR) for bladder cancer is 10.1 cases per 100,000 men and 2.5 cases per 100,000 women, with a mortality rate of 4 deaths per 100,000 men and 1.1 deaths per 100,000 women.4 Most bladder tumors
Cost of management of low-grade bladder cancer
Depending on the model and breadth of features included, bladder cancer has been estimated as the most expensive cancer to health care systems, with a mean cost to Medicare of $96,000 to $187,000 per patient in 2001.15 In the United States, the total estimated cost in 2006 was $206 billion, with predicted productivity loss of $17.9 billion, and cancer-related morbidity of $110 billion.16 The majority of the cost for bladder cancer is hospital-based transurethral resection of a bladder tumor
Identification of patients for office-based management of bladder cancer
The critical factor to determine the suitability of office-based management of bladder cancer is an accurate assessment of risk of progression. Although the initial identification of bladder cancer occurs in the office, the authors recommend outpatient TUR with examination under anesthesia for complete and accurate staging. Based on TUR pathology, tumors amenable to office-based management are papillomas, PUNLMP, and TaLG tumors. The main concern with office-based management is missing
Effectiveness and tolerability of office-based management
Herr described the use of office-based cystoscopy with fulguration in 69 patients with both high- and low-grade lesions, some of which demonstrated invasion.24 Of the 32% of patients who required TUR, 5 had CIS, and 3 had muscle invasion. Office-based fulguration was the only intervention in 68% of patients, with 30% of patients requiring repeat treatment. In a prospective study of 267 patients carefully selected (as per the Donat criteria), office-based fulguration was the only intervention
Watchful waiting of identified bladder tumors
Some patients with small or low-grade bladders tumors may be watched without the need for TUR or cystodiathermy after identification of new tumors. Soloway and colleagues27 described observation of 32 patients with a mean duration of 10.8 months, and patients undergoing an average of 1.8 interval cystoscopies between treatments (range of 1–5). Importantly, the authors described a tumor growth rate of 1.77 mm per month, with a progression rate of 6.7%. Gofrit and colleagues28 described the
Frequency and timing of follow-up and tumor surveillance
No prospective randomized trials have demonstrated sufficient level of evidence to support a specific surveillance protocol for the management of noninvasive bladder tumors. The goals of surveillance would be to minimize the cost and psychological burden of surveillance, tempered by prudent follow-up to prevent growth of tumors necessitating inpatient TUR. From watchful waiting studies, it has been noted that small tumors (<5 mm) may be observed for almost 10 months without intervention.28 Yet,
Voided biomarkers for surveillance
The use of prognostic biomarkers could potentially play a critical role in the management of patients with low-grade bladder cancer. Invasive procedures, such as cystoscopy, could potentially be avoided if a biomarker reliably had a high negative predictive value. There are several biomarkers approved for surveillance by the US Food and Drug Administration. Voided cytology has a long-documented role in the identification of high-grade bladder cancer and can be used to identify patients who
Routine imaging for surveillance
Progression of low-grade bladder cancer to upper tract or extravesical tumors occurs at at a frequency of 40% at 15 years, including upper tract and prostate involvement.37 In low-grade disease, this risk of upper tract progression was 8%, with a median time to development of 29 months.8 The EAU recommends no upper tract surveillance for low-risk tumors but yearly surveillance for high-risk bladder cancer.4 The rate of upper tract progression increases yearly, and although routine surveillance
Antibiotics, prophylaxis, and drug resistance
Asymptomatic bacteria is commonly found in elderly patients, and those instrumented for malignancy may be at an increased risk for symptomatic infection.39 Patients with bladder cancer will undergo many cystoscopies during their lifetime, and unsupervised use of antibiotics to treat colonization rather than infection, even when given for procedural prophylaxis, may result in multidrug bacterial resistance. Routine use of antibiotics is recommended by the American Urological Association (AUA)
Lifestyle modification
One of the most important lifestyle changes the urologist can contribute to the overall health of patients and potentially decrease the rates of bladder tumor recurrence is counseling for smoking cessation. Duration and intensity of smoking are directly correlated to bladder cancer recurrence in patients with noninvasive bladder cancer.43 Patients report poor knowledge regarding the association with smoking and their bladder cancer, and most describe increased readiness to quit if they knew
Narrow-band imaging
Narrow-band imaging (NBI) is an optical technology that employs filtering of white light into 2 narrow bands (440–460 nm and 540–560 nm) that are absorbed by hemoglobin, resulting in visual detection of increased vascularity with tumors. NBI cystoscopy increases detection of tumors resulting in decreased rates of recurrence of superficial bladder tumors.52 Unlike other forms of fluorescent-based imaging, NBI does not require instillation of a precursor reagent and only requires a special filter
Summary
As more is learned about the biology and natural history of bladder cancer, office-based management is becoming more widely used for low-grade and -stage lesions. Clinical decision making should be based on risk stratification. Low-risk patients can be safely followed on a semiannual or even yearly basis. Patients with high-risk tumors require more stringent cystoscopic surveillance, cytology, and yearly upper tract imaging. Smoking cessation is an invaluable tool to decrease rates of
References (55)
- et al.
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update
Eur Urol
(2011) - et al.
Bladder cancer: epidemiology, staging and grading, and diagnosis
Urology
(2005) - et al.
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials
Eur Urol
(2006) - et al.
Recurrence and progression in low grade papillary urothelial tumors
J Urol
(1999) - et al.
Management of low grade papillary bladder tumors
J Urol
(2007) - et al.
Treated history of noninvasive grade 1 transitional cell carcinoma. The National Bladder Cancer Group
J Urol
(1992) - et al.
Prognostic factors in superficial bladder tumors. A study of the European Organization for Research on Treatment of Cancer: Genitourinary Tract Cancer Cooperative Group
J Urol
(1983) - et al.
Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party)
J Urol
(1989) - et al.
Adjuvant chemotherapy of superficial transitional cell bladder carcinoma: preliminary results of a European organization for research on treatment of cancer. Randomized trial comparing doxorubicin hydrochloride, ethoglucid and transurethral resection alone
J Urol
(1984) - et al.
Primary superficial bladder cancer risk groups according to progression, mortality and recurrence
J Urol
(2000)
Efficacy of office fulguration for recurrent low grade papillary bladder tumors less than 0.5 cm
J Urol
Correlation of cystoscopy with histology of recurrent papillary tumors of the bladder
J Urol
Correlation of cystoscopic impression with histologic diagnosis of biopsy specimens of the bladder
Hum Pathol
Outpatient flexible cystoscopy and fulguration of recurrent superficial bladder tumors
J Urol
A prospective trial of flexible cystodiathermy for recurrent transitional cell carcinoma of the bladder
J Urol
Expectant management of small, recurrent, noninvasive papillary bladder tumors
J Urol
Watchful waiting policy in recurrent Ta G1 bladder tumors
Eur Urol
Conservative management of low risk superficial bladder tumors
J Urol
Urine cytology. It is still the gold standard for screening?
Urol Clin North Am
Urine markers for bladder cancer surveillance: a systematic review
Eur Urol
Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer
J Urol
Use of urinary biomarkers for bladder cancer surveillance: patient perspectives
J Urol
Best practice policy statement on urologic surgery antimicrobial prophylaxis
J Urol
Impact of smoking on outcomes of patients with a history of recurrent nonmuscle invasive bladder cancer
J Urol
Brief smoking cessation intervention: a prospective trial in the urology setting
J Urol
Impact of smoking and smoking cessation on oncologic outcomes in primary non-muscle-invasive bladder cancer
Eur Urol
Protective effects of plasma carotenoids on the risk of bladder cancer
J Urol
Cited by (9)
Bladder Biopsy of Normal-Appearing Mucosa is Not Helpful in Patients with Unexplained Positive Cytology after Nonmuscle Invasive Bladder Cancer
2015, Journal of UrologyCitation Excerpt :Notably transurethral bladder biopsy is not without drawbacks. Uninformative biopsies add expense and morbidity to the management of this disease, which is already one of the most expensive cancers during a lifetime.5,6 Most of the cost of managing bladder cancer originates from cystoscopic surveillance and hospital based TURBT for superficial disease.7
TULA DUAL: Trans Urethral Laser Ablation of recurrent bladder tumors in outpatient setting
2023, Archivio Italiano di Urologia e AndrologiaBladder cancer: Risk factors, diagnosis, and management
2017, Nurse Practitioner
Disclosures: None.
Funding: Dr Herr is supported by the Sidney Kimmel Center for Prostate and Urologic Cancers.
Conflicts: None.